INCOME TAXES (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Deferred Tax Asset, attributable to net operating loss carry forwards	$ 5,852,116
Net operating loss carry forwards	17,212,108
Net Operating Loss Carry forwards acquired in reverse acquisition of BMSG	38,616
Net Operating Loss Carry forwards attributable to Bio-Matrix Scientific Group, Inc., BMSG, Regen and Entest	17,173,492
Deferred tax assets, reduced from recorded valuation allowance	$ 0
Federal Corporate Rate Income tax	34.00%